# A Phase Ib Study of Fruquintinib in 3rd Line mCRC

> **NCT01975077** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 62 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** fruquintinib

## Key facts

- **NCT ID:** NCT01975077
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01975077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01975077, "A Phase Ib Study of Fruquintinib in 3rd Line mCRC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01975077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*